Bilandzic, A. et Fitzpatrick, T. et Rosella, L. et Henry, D. (2016). Risk of bias in systematic reviews of non-randomized studies of adverse cardiovascular effects of thiazolidinediones and cyclooxygenase-2 inhibitors: application of a new Cochrane risk of bias tool. PLOS Medicine, 13 (4). DOI: 10.1371/journal.pmed.1001987.
Le plein texte n'est pas disponible pour ce document.Résumé
Systematic reviews of the effects of healthcare interventions frequently include non-randomized studies. These are subject to confounding and a range of other biases that are seldom considered in detail when synthesizing and interpreting the results. Our aims were to assess the reliability and usability of a new Cochrane risk of bias (RoB) tool for non-randomized studies of interventions and to determine whether restricting analysis to studies with low or moderate RoB made a material difference to the results of the reviews.
| Type de document: | Article |
|---|---|
| Mots-clés libres: | VAPEN Cardiovascular Risk of bias Thiazolidinediones Inhibitors Cyclooxygenase-2 Inhibitors |
| Déposé par: | Veille References |
| Date de dépôt: | 09 mars 2017 13:42 |
| Dernière modification: | 09 mars 2017 13:42 |
| URI: | https://bel.uqtr.ca/id/eprint/3037 |
Gestion Actions (Identification requise)
 |
Dernière vérification avant le dépôt |